Myriad Genetics, Inc. (MYGN): Price and Financial Metrics
MYGN Price/Volume Stats
| Current price | $26.39 | 52-week high | $29.08 |
| Prev. close | $26.28 | 52-week low | $13.82 |
| Day low | $26.00 | Volume | 565,782 |
| Day high | $26.55 | Avg. volume | 720,230 |
| 50-day MA | $27.11 | Dividend yield | N/A |
| 200-day MA | $22.83 | Market Cap | 2.39B |
MYGN Stock Price Chart Interactive Chart >
Myriad Genetics, Inc. (MYGN) Company Bio
Myriad Genetics discovers and commercializes molecular diagnostic tests that; determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties to improve patient care. The company was founded in 1991 and is based in Salt Lake City, Utah.
Latest MYGN News From Around the Web
Below are the latest news stories about MYRIAD GENETICS INC that investors may wish to consider to help them evaluate MYGN as an investment opportunity.
Genetic Testing Pioneer Myriad Genetics' Evolution Draws Analyst Attention Amid New Product(s) AnticipationPiper Sandler initiated coverage on Myriad Genetics Inc (NASDAQ: MYGN), noting that many investors know the company as one of the earliest pioneers of genetic testing. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions. The company offers tests across multiple categories, including hereditary cancer, pharmacogenomics, and women’s health. It pioneered and was the market leader in BRCA testing for over ten y |
Myriad Genetics' (MYGN) New Platform to Advance Cancer CareMyriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results. |
Myriad Genetics Chief Financial Officer Bryan Riggsbee Retires; Scott Leffler Appointed as Successor; Reiterates Previously Issued Financial GuidanceScott Leffler Myriad Genetics, Inc., a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective January 29, 2024. Leffler will succeed Myriad CFO Bryan Riggsbee who is retiring. SALT LAKE CITY, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Scott Leffler as Chief Financial Officer (CFO), effective Ja |
Myriad Genetics Establishes Comprehensive Pan-Cancer Research Platform to Advance Patient CareThe Myriad Collaborative Research Registry has more than one million patient casesSALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of the Myriad Collaborative Research Registry™ (MCRR). Formerly known as the Precise Treatment Registry, the MCRR includes new data across germline and tumor testing results from Myriad’s cancer products on more than one million patients. The latest e |
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX WoesMyriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test. |
MYGN Price Returns
| 1-mo | -6.35% |
| 3-mo | 13.75% |
| 6-mo | 24.72% |
| 1-year | 64.94% |
| 3-year | -19.30% |
| 5-year | -3.76% |
| YTD | 37.88% |
| 2023 | 31.91% |
| 2022 | -47.43% |
| 2021 | 39.57% |
| 2020 | -27.38% |
| 2019 | -6.33% |
Continue Researching MYGN
Want to do more research on Myriad Genetics Inc's stock and its price? Try the links below:Myriad Genetics Inc (MYGN) Stock Price | Nasdaq
Myriad Genetics Inc (MYGN) Stock Quote, History and News - Yahoo Finance
Myriad Genetics Inc (MYGN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...